CureVac N.V. CVAC 深 滬
已收盤 09-26 16:00:00 美东时间
5.37
+0.020
+0.37%
華盛通- 最 高5.38
- 今 開5.36
- 成交量 35.26万股
- 最 低 5.34
- 昨 收 5.35
- 總市值 12.08亿
- 52周最高 5.72
- 市盈率 靜 6.87
- 換手率 0.16%
- 52周最低 2.37
- 委 比 -22.84%
- 總股本 2.25亿
- 歷史最高 151.80
- 量 比 1.01
- 振 幅 0.75%
- 歷史最低 2.215
- 每 手 1
- 風險率 1.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioNTech杀疯了
（来源：药剂Talks） mRNA疫苗巨头BioNTech正在狂奔。 6月2日，百时美施贵宝（BMS）宣布就PD-L1/VEGF双抗BNT327（普米斯生物的...
09-12 09:15
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
09-05 21:09
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Cassava Sciences, Inc. announced that its CEO, Rick Barry, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8, 2025. The event will feature a corporate presentation at 5 PM ET, available via webcast and replay on Cassava's investor website for 90 days. Cassava, a biotechnology company focused on CNS disorder treatments, is based in Austin, Texas.
08-25 12:00
CureVac Reports Financial Losses in Mid-2025
CureVac ( ($CVAC) ) has issued an update. CureVac N.V. released its unaudited i...
08-16 04:43
CureVac Reports Q2 Revenues Of EUR1.2M, Lower Than EUR14.4M YoY
The decrease year-over-year was primarily driven by lower revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licensing Agreement as well as lower sales to CRISPR
08-15 19:58
BioNTech Settles Patent Disputes with CureVac and GSK
BioNTech SE ( ($BNTX) ) has provided an update. On August 7, 2025, BioNTech SE,...
08-11 18:43
氪星晚报｜印度科技巨头塔塔咨询裁员预示人工智能将重塑2830亿美元外包行业；中国工商银行与新开发银行举行工作会谈；CureVac就新冠疫苗专利与BioNTech、辉瑞达成和解
大公司： 京东物流在福州成立供应链科技公司 36氪获悉，爱企查App显示，近日，福州京迅递供应链科技有限公司成立，法定代表人为张明明，注册资本500万元人民币...
08-08 19:17
CureVac与辉瑞/BioNTech专利纠纷达成和解 葛兰素史克(GSK.US)获高额赔偿
CureVac已与辉瑞和BioNTech在美国就mRNA疫苗的长期专利纠纷达成和解协议，这将使CureVac的前合作伙伴葛兰素史克获得最多5亿美元以及未来疫苗销售1%的版税收入。
08-08 16:51
